| |
|
|
A BILL TO BE ENTITLED
|
|
|
AN ACT
|
|
|
relating to the addition of Salvinorin A and Salvia divinorum to |
|
|
Penalty Group 3 of the Texas Controlled Substances Act. |
|
|
BE IT ENACTED BY THE LEGISLATURE OF THE STATE OF TEXAS: |
|
|
SECTION 1. Section 481.104(a), Health and Safety Code, is |
|
|
amended to read as follows: |
|
|
(a) Penalty Group 3 consists of: |
|
|
(1) a material, compound, mixture, or preparation that |
|
|
contains any quantity of the following substances having a |
|
|
potential for abuse associated with a stimulant effect on the |
|
|
central nervous system: |
|
|
Methylphenidate and its salts; and |
|
|
Phenmetrazine and its salts; |
|
|
(2) a material, compound, mixture, or preparation that |
|
|
contains any quantity of the following substances having a |
|
|
potential for abuse associated with a depressant effect on the |
|
|
central nervous system: |
|
|
a substance that contains any quantity of a |
|
|
derivative of barbituric acid, or any salt of a derivative of |
|
|
barbituric acid not otherwise described by this subsection; |
|
|
a compound, mixture, or preparation containing |
|
|
amobarbital, secobarbital, pentobarbital, or any salt of any of |
|
|
these, and one or more active medicinal ingredients that are not |
|
|
listed in any penalty group; |
|
|
a suppository dosage form containing amobarbital, |
|
|
secobarbital, pentobarbital, or any salt of any of these drugs, and |
|
|
approved by the United States Food and Drug Administration for |
|
|
marketing only as a suppository; |
|
|
Alprazolam; |
|
|
Amobarbital; |
|
|
Bromazepam; |
|
|
Camazepam; |
|
|
Chlordiazepoxide; |
|
|
Chlorhexadol; |
|
|
Clobazam; |
|
|
Clonazepam; |
|
|
Clorazepate; |
|
|
Clotiazepam; |
|
|
Cloxazolam; |
|
|
Delorazepam; |
|
|
Diazepam; |
|
|
Estazolam; |
|
|
Ethyl loflazepate; |
|
|
Fludiazepam; |
|
|
Flurazepam; |
|
|
Glutethimide; |
|
|
Halazepam; |
|
|
Haloxzolam; |
|
|
Ketazolam; |
|
|
Loprazolam; |
|
|
Lorazepam; |
|
|
Lormetazepam; |
|
|
Lysergic acid, including its salts, isomers, and |
|
|
salts of isomers; |
|
|
Lysergic acid amide, including its salts, |
|
|
isomers, and salts of isomers; |
|
|
Mebutamate; |
|
|
Medazepam; |
|
|
Methyprylon; |
|
|
Midazolam; |
|
|
Nimetazepam; |
|
|
Nitrazepam; |
|
|
Nordiazepam; |
|
|
Oxazepam; |
|
|
Oxazolam; |
|
|
Pentazocine, its salts, derivatives, or compounds |
|
|
or mixtures thereof; |
|
|
Pentobarbital; |
|
|
Pinazepam; |
|
|
Prazepam; |
|
|
Quazepam; |
|
|
Secobarbital; |
|
|
Sulfondiethylmethane; |
|
|
Sulfonethylmethane; |
|
|
Sulfonmethane; |
|
|
Temazepam; |
|
|
Tetrazepam; |
|
|
Tiletamine and zolazepam in combination, and its |
|
|
salts. (some trade or other names for a tiletamine-zolazepam |
|
|
combination product: Telazol, for tiletamine: |
|
|
2-(ethylamino)-2-(2-thienyl)-cyclohexanone, and for zolazepam: |
|
|
4-(2-fluorophenyl)-6, |
|
|
8-dihydro-1,3,8,-trimethylpyrazolo-[3,4-e](1,4)-d |
|
|
diazepin-7(1H)-one, flupyrazapon); |
|
|
Triazolam; |
|
|
Zaleplon; and |
|
|
Zolpidem; |
|
|
(3) Nalorphine; |
|
|
(4) a material, compound, mixture, or preparation |
|
|
containing limited quantities of the following narcotic drugs, or |
|
|
any of their salts: |
|
|
not more than 1.8 grams of codeine, or any of its |
|
|
salts, per 100 milliliters or not more than 90 milligrams per dosage |
|
|
unit, with an equal or greater quantity of an isoquinoline alkaloid |
|
|
of opium; |
|
|
not more than 1.8 grams of codeine, or any of its |
|
|
salts, per 100 milliliters or not more than 90 milligrams per dosage |
|
|
unit, with one or more active, nonnarcotic ingredients in |
|
|
recognized therapeutic amounts; |
|
|
not more than 300 milligrams of dihydrocodeinone |
|
|
(hydrocodone), or any of its salts, per 100 milliliters or not more |
|
|
than 15 milligrams per dosage unit, with a fourfold or greater |
|
|
quantity of an isoquinoline alkaloid of opium; |
|
|
not more than 300 milligrams of dihydrocodeinone |
|
|
(hydrocodone), or any of its salts, per 100 milliliters or not more |
|
|
than 15 milligrams per dosage unit, with one or more active, |
|
|
nonnarcotic ingredients in recognized therapeutic amounts; |
|
|
not more than 1.8 grams of dihydrocodeine, or any |
|
|
of its salts, per 100 milliliters or not more than 90 milligrams per |
|
|
dosage unit, with one or more active, nonnarcotic ingredients in |
|
|
recognized therapeutic amounts; |
|
|
not more than 300 milligrams of ethylmorphine, or |
|
|
any of its salts, per 100 milliliters or not more than 15 milligrams |
|
|
per dosage unit, with one or more active, nonnarcotic ingredients |
|
|
in recognized therapeutic amounts; |
|
|
not more than 500 milligrams of opium per 100 |
|
|
milliliters or per 100 grams, or not more than 25 milligrams per |
|
|
dosage unit, with one or more active, nonnarcotic ingredients in |
|
|
recognized therapeutic amounts; |
|
|
not more than 50 milligrams of morphine, or any of |
|
|
its salts, per 100 milliliters or per 100 grams with one or more |
|
|
active, nonnarcotic ingredients in recognized therapeutic amounts; |
|
|
and |
|
|
not more than 1 milligram of difenoxin and not |
|
|
less than 25 micrograms of atropine sulfate per dosage unit; |
|
|
(5) a material, compound, mixture, or preparation that |
|
|
contains any quantity of the following substances: |
|
|
Barbital; |
|
|
Chloral betaine; |
|
|
Chloral hydrate; |
|
|
Ethchlorvynol; |
|
|
Ethinamate; |
|
|
Meprobamate; |
|
|
Methohexital; |
|
|
Methylphenobarbital (Mephobarbital); |
|
|
Paraldehyde; |
|
|
Petrichloral; and |
|
|
Phenobarbital; |
|
|
(6) Peyote, unless unharvested and growing in its |
|
|
natural state, meaning all parts of the plant classified |
|
|
botanically as Lophophora, whether growing or not, the seeds of the |
|
|
plant, an extract from a part of the plant, and every compound, |
|
|
manufacture, salt, derivative, mixture, or preparation of the |
|
|
plant, its seeds, or extracts; |
|
|
(7) unless listed in another penalty group, a |
|
|
material, compound, mixture, or preparation that contains any |
|
|
quantity of the following substances having a stimulant effect on |
|
|
the central nervous system, including the substance's salts, |
|
|
optical, position, or geometric isomers, and salts of the |
|
|
substance's isomers, if the existence of the salts, isomers, and |
|
|
salts of isomers is possible within the specific chemical |
|
|
designation: |
|
|
Benzphetamine; |
|
|
Cathine [(+)-norpseudoephedrine]; |
|
|
Chlorphentermine; |
|
|
Clortermine; |
|
|
Diethylpropion; |
|
|
Fencamfamin; |
|
|
Fenfluramine; |
|
|
Fenproporex; |
|
|
Mazindol; |
|
|
Mefenorex; |
|
|
Modafinil; |
|
|
Pemoline (including organometallic complexes and |
|
|
their chelates); |
|
|
Phendimetrazine; |
|
|
Phentermine; |
|
|
Pipradrol; |
|
|
Sibutramine; and |
|
|
SPA [(-)-1-dimethylamino-1,2-diphenylethane]; |
|
|
(8) unless specifically excepted or unless listed in |
|
|
another penalty group, a material, compound, mixture, or |
|
|
preparation that contains any quantity of the following substance, |
|
|
including its salts: |
|
|
Dextropropoxyphene (Alpha-(+)- |
|
|
4-dimethylamino-1,2-diphenyl-3-methyl-2-propionoxybutane); [and] |
|
|
(9) an anabolic steroid or any substance that is |
|
|
chemically or pharmacologically related to testosterone, other |
|
|
than an estrogen, progestin, or corticosteroid, and promotes muscle |
|
|
growth, including: |
|
|
Boldenone; |
|
|
Chlorotestosterone (4-chlortestosterone); |
|
|
Clostebol; |
|
|
Dehydrochlormethyltestosterone; |
|
|
Dihydrotestosterone (4-dihydrotestosterone); |
|
|
Drostanolone; |
|
|
Ethylestrenol; |
|
|
Fluoxymesterone; |
|
|
Formebulone; |
|
|
Mesterolone; |
|
|
Methandienone; |
|
|
Methandranone; |
|
|
Methandriol; |
|
|
Methandrostenolone; |
|
|
Methenolone; |
|
|
Methyltestosterone; |
|
|
Mibolerone; |
|
|
Nandrolone; |
|
|
Norethandrolone; |
|
|
Oxandrolone; |
|
|
Oxymesterone; |
|
|
Oxymetholone; |
|
|
Stanolone; |
|
|
Stanozolol; |
|
|
Testolactone; |
|
|
Testosterone; and |
|
|
Trenbolone; |
|
|
(10) Salvinorin A; and |
|
|
(11) Salvia divinorum. |
|
|
SECTION 2. This Act takes effect September 1, 2007. |